Non-small cell lung cancer is one of the most common types of lung cancer that occurs in both smokers and non-smokers. Immune checkpoint inhibitors have emerged as an effective treatment for NSCLC, but they have been associated with multisystem immune-related adverse events (irAEs). This study aims to determine the association of multisystem irAEs with survival and risk factors.

This retrospective cohort study included a total of 623 patients with stage III/IV NSCLC who were treated with anti–PD-(L)1 ICIs. The primary outcome of the study was the diagnosis of multisystem irAEs as characterized by the combinations of individual irAEs involved.

The findings suggested that 148 patients (24%) developed a single irAE, and 58 patients (9.3%) developed multisystem iRAWs. Pneumonitis thyroiditis, dermatitis pneumonitis, hepatitis thyroiditis, and dermatitis thyroiditis were the most common multisystem irAE patterns. A longer duration of immune checkpoint inhibitors was an independent risk factor for the development of multisystem irAEs. Besides, patients with 1 irAE and multisystem irAEs had a statistically improved overall survival and progression-free survival compared with patients with no irAEs.

For latest news and updates

The research concluded that the development of multisystem irAEs was linked to improved survival in patients with NSCLC with immune checkpoint inhibitors.